Dried blood spots for erythropoietin analysis: Detection of micro-doses, EPO c.577del variant and comparison with in-competition matching urine samples
Heiland et al.
The finding, in our words
Capillary dried blood spots collected during professional triathlon competitions detected endogenous erythropoietin in all 111 athletes using Tasso-M20 devices, even when matching urine samples were negative. Mitra VAMS devices also sensitively detected recombinant EPO micro-doses and the EPO c.577del variant, confirming that microsampling provides a viable complementary matrix for decentralised doping analysis.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
Capillary samples collected using dried blood spots and Mitra microsamplers showed strong agreement with venous plasma for quantifying IgG antibodies against most vaccine-preventable diseases. Sensitivity was high for the majority of pathogens, though the study noted that antibody stability declined at room temperature over time, favouring cold storage for longer durations.
A validated two-step LC-MS/MS protocol can identify 91 prohibited doping agents from a single dried blood spot collected on either cellulose cards or volumetric absorptive microsampling devices. This demonstrates robust multi-analyte screening from capillary blood, supporting decentralised anti-doping programmes where venous sampling is impractical.
In matched clinical samples from rheumatoid arthritis, VAMS and DBS showed strong agreement for methotrexate polyglutamates (slopes 0.95-1.07; bias within -4.21% to 0.36%; SRCC ≥ 0.969), with up to 100% of total MTXPG results within ±20% limits; capillary microsampling agreed closely with whole blood but differed from red blood cells, indicating matrix-specific differences that must be accounted for when interpreting against RBC-based reference values.
This study validated a method for measuring the alcohol biomarker phosphatidylethanol using two volumetric absorptive microsampling devices, finding that the Mitra device met all validation criteria and agreed with venous sampling. The Capitainer device was deemed suitable but showed reduced accuracy at higher concentrations, with a small proportional negative bias compared to venous results.